ArticleClinical Medicine Insights. Oncology2024
The Influence of Cancer Type on Stroke Incidence: A Retrospective Study.
Article in Clinical Medicine Insights. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stroke secondary to cancer-associated coagulopathy: a systematic review.Journal of neurology · 2026Pooled it
- Recanalization therapy in stroke patients with malignancies: in-hospital outcomes by cancer subtype in a nationwide administrative data analysis.Journal of neurology · 2026Article
- Clinical features and prognosis of patients with malignant tumors complicated by cerebral infarction.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study is to examine the hematological and biochemical variables in patients diagnosed with cancer-related stroke who have different types of cancer and to evaluate the effects of these variables. Methods: This retrospective study was conducted at a tertiary hospital stroke center and included 153 patients diagnosed with cancer-related stroke. Comprehensive etiological investigations were performed, and patients were classified according to the Trial of Org 101072 in Acute Stroke Treatment (TOAST) classification. Laboratory parameters including d-dimer, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fibrinogen levels were collected from blood samples taken at the time of stroke. Statistical analysis was performed using 1-way analysis of variance to assess differences in laboratory parameters across different cancer types. Results: The study found significant variations in hematological and biochemical parameters among different cancer types. Specifically, glomerular filtration rate, activated partial thromboplastin time, prothrombin time, and international normalized ratio levels showed significant differences across cancer types ( Conclusions: This retrospective study highlights the importance of considering cancer-specific factors in the management of stroke risk, particularly in cancers such as pancreatic and colon, which show a predisposition to earlier stroke occurrence. The elevated coagulation factors in these patients suggest the potential need for early preventive treatment with anticoagulants or thrombin inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.